The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class Ⅲ β-tubulin protein expression in non-small cell lung cancer patients

Objective To investigate the predictive value of breast cancer susceptibility gene 1 (BRCA1) and class Ⅲβ-tubulin protein expression in tumor tissue for the efficacy of taxol and cisplatin combined chemotherapy (TP) in stage Ⅲβ/Ⅳ non-small cell lung cancer(NSCLC) patients. Methods A total of 92 stage Ⅲβ/Ⅳ NSCLC patients were recruited with 87 patients evaluated. Bronchoscopy or lung puncture tumor biopsy samples were obtained with BRCA1 and class Ⅲβ-tubulin protein expression examined immunohistochemically before chemotherapy. The patients were randomly assigned to be received 4 to 6 cycles of TP chemotherapy regiments and followed up until death or lost. Response rate (RR) , overall survival (OS) and time to tumor progression (TTP) were assessed. Results Among the 87 evaluated patients, the positive expression rates of BRCA1 and class Ⅲβ-tubulin were 57. 5% (50/87) and 48. 3%(42/87) respectively. There was no significant difference in clinical characteristics among patients with different positive expression rate. According to different expression of BRCA1 and class Ⅲβ-tubulin, the patients were divided into four groups: group A (low expression of both BRCA1 and class 1 p-tubulin) ,group B (high expression of both BRCA1 and class Ⅲβ-tubulin) , group C (high expression of only BRCA1) and group D (high expression of only class Ⅲβ-tubulin). The RR was higher in group A than other three groups (60. 7% , 34. 8% , 9/19 and 6/17 respectively). The OS and TTP were longer in group A than other three groups [OS: (539. 4 ± 17. 6) days, (267. 2 ± 20. 5) days, (325. 6 ± 24. 1) days and (283.7±26.2) days respectively ; TTP: (256. 9 ± 28. 4) days, (143.8±17.6) days, (179. 3 ± 19. 8)days and (152. 6 ±23. 5) days respectively]. There were no significant differences among the other three groups. Conclusions The expression level of BRCA1 and class Ⅲβ-tubulin in tumor tissue is probably a predictor for the efficacy of TP chemotherapy in NSCLC patients. TP chemotherapy is more suitable for the NSCLC patients with lower expression of both BRCA1 and class Ⅲβ-tubulin. Our study may provide a new sight for tailored chemotherapy in NSCLC patients.     

高血压脑出血脑积水78例的治疗体会

[目的]探讨高血压脑出血早期救治和中后期脑积水的诊治的方法与疗效.[方法]收集本院78例高血压脑出血出现脑积水患者的临床资料并对其治疗情况进行回顾性分析.[结果]78例高血压脑出血出现脑积水的患者中,丘脑出血59例,脑干出血13例,小脑出血6例.所有病例均有出血破入脑室系统,其中侧脑室、第三脑室、导水管及第四脑室全脑室铸型53例;发生颅内感染36例.早期行侧脑室引流、冲洗、尿激酶注入、腰穿治疗,侧脑室引流持续时间7～56 d;中后期出现脑积水46例,均给予侧脑室腹腔分流术.本组病例中中度残废36例,重度残废18例,持续植物状态15例,死亡9例.[结论]高血压脑出血发生脑积水与出血部位、出血破入脑室系统和继发颅内感染有关,早期积极引流、预防感染,中后期及时给予侧脑室腹腔分流术有助于改善预后.     

中药与刺血术结合治疗妇女青春期癫狂3例

癫狂病西医治疗期间由于过多地服用强效安神镇静剂而并发后遗症 ,给病者家庭各方面带来负担。我科采用桃核承气汤加味 ,结合重庆少林堂老中医刘少林的刺血术 ,于 2 0 0 1年 8～ 9月 ,治疗 3例 ,效果理想。报道如下。1　临床资料3例病人 ,年龄 16岁 1例 ,18岁 2例 ,在精神病院治疗最短 2 0天 ,最长 2个月。2　治疗方法中药处方 :桃仁泥、大黄、丹参、益母草各 30ｇ ,芒硝 18ｇ(另包分冲 ) ,醋制香附、黄芩各15ｇ ,栀子、郁金、丹皮、桂枝各 12ｇ ,甘草 9ｇ ,每日 1剂 ,水煎分早、中、晚 3次服。刺血术 :三棱针刺大椎、委中出血 ,然后拔罐 15…     

前列腺炎搭上“蜜月车”

相恋的人经过漫长的酿造终于在结婚的时刻尝到了爱情之蜜。五月是传统的品“蜜”高峰期,在这幸福的时刻,身心健康是体味甜蜜的保障,尤其是新郎们,一定要当心——     

城市 人口 疾病

翔’芦3,瀚豢鬻 4 几百万消费者要在同一个时间里购买物资,就有一个谁先购买的问题;如果供应物品短缺,又势必会引起精神上的紧迫感,焦急、烦恼、妒忌等便随之而来。≮≮ 7 以上各种紧张的精神状态是疾病之源。据统计,所有求诊病人中,因精神紧张而致病的占百分之七十六,因精神或情绪而住院的比躯体与外伤患者多。城市 人口 疾病@连生 @万一兵     

肩胛骨骨皮瓣吻合血管移植

我们在肩胛旁皮瓣吻合血管移植用于临床的基础上,设计了一种肩胛骨骨皮瓣,于1982年12月用这种骨皮瓣修复1例右手2、3掌骨及手背软组织缺损的患者,获得成活。经6个月观察,用肩胛骨外侧缘骨瓣修复掌骨,其位置形态满意,10周X线照片骨瓣与受区骨质已经连接,肩关节功能未受影响,相继又做2例,均获成功。结合临床,我们对300个成人肩胛骨,154侧成人肩胛部血供及两侧新鲜尸体旋肩胛动脉墨汁灌注标本进行了应用解剖学研究。认为肩胛骨外侧缘是较为理想的供骨部位,旋肩胛血管束是此部骨移植的主要吻接血管。旋肩胛动脉具有一般体壁血管走行的规律性,分为深浅二支,深支入骨(肌),浅支入皮,从而为肩胛骨骨皮瓣吻合血管移植提供了应用解剖学的血供依据。     

多西紫杉醇联合奥沙利铂和5-氟尿嘧啶的DOF方案治疗晚期胃癌的初步研究

目的:观察多西紫杉醇(DOC)联合奥沙利铂(L-OHP)和5-氟尿嘧啶(5-Fu)的DOF方案治疗晚期胃癌的临床疗效和不良反应?方法:化疗方案 DOC 75 mg/m2(第1天),L-OHP 130 mg/m2(第1天),5-Fu 2.5 g/m2,持续静脉滴注120 h,21 d为1个周期,至少应用2个周期,进行疗效评价并评估反应?结果:全组73例均可评价疗效,总有效率为68.5%,其中完全缓解(CR)18例(24.7%),部分缓解(PR)32例(43.8%),至肿瘤进展时间为9.2个月,中位生存期为13.7个月?初治的46例有效率为76.1%,复治的27例有效率为55.5%?主要不良反应为骨髓抑制?口腔黏膜炎和周围神经毒性反应,其中Ⅲ~Ⅳ度白细胞下降率为26.0%,无治疗相关性死亡?结论:DOF方案是晚期胃癌的有效化疗方案,不良反应易于耐受?     

青藤碱肠溶片在Beagle犬体内药动学研究

目的:研究口服青藤碱肠溶片在Beagle犬体内的药动学。方法:8只Beagle犬口服青藤碱肠溶片(10mg·kg-1)0、15、30、60、90、120、240、480min后分别从前肢静脉取血2mL,采用高效液相色谱法测定并计算血药浓度,用3p97软件计算药动学参数。结果:青藤碱肠溶片在犬体内药-时曲线符合一室模型,主要药动学参数tmax为(69.66±16.41)min,Cmax为(0.13±0.02)μg·mL-1,t1/2ke为(87.62±28.26)min,AUC0～T为(28.43±3.48)μg·min·mL-1。结论:Beagle犬口服青藤碱肠溶片后在体内吸收迅速,消除较快。